Botulinum Toxin Brands in the U.S.
Botulinum toxin brands are product identities, not interchangeable names for one medicine. Each product has its own manufacturer or commercialization path, toxin type, potency assay, label, formulation, and market history.
The U.S. brand map is especially useful because several products are often compared in aesthetic practice even though their units and labels remain product-specific. Shared type A biology does not make Botox, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo unit-equivalent.
U.S. Regulatory Reference
Section titled “U.S. Regulatory Reference”| Reference | Main question |
|---|---|
| U.S. FDA approval timeline | When did each FDA-approved product or major indication enter the U.S. approval record? |
| U.S. FDA indication matrix | Which indications and patient limits appear in each current U.S. label? |
| U.S. botulinum toxin regulatory status | Which products are approved, which public BLAs received CRLs, and which programs remain in resubmission planning? |
U.S. Aesthetic Type A Brands
Section titled “U.S. Aesthetic Type A Brands”| Brand | U.S. approval anchor | Manufacturer / commercialization context | Product identity |
|---|---|---|---|
| Botox | 1989 therapeutic Botox 🔗; 2002 Botox Cosmetic approval 🔗 | AbbVie / Allergan | OnabotulinumtoxinA reference brand with broad therapeutic and aesthetic visibility. |
| Dysport | 2009 U.S. label anchor 🔗 | Ipsen product context; Galderma U.S. aesthetic commercialization | AbobotulinumtoxinA product with a long global comparison history. |
| Xeomin | 2010 U.S. label anchor 🔗 | Merz Pharmaceuticals GmbH manufacturing; Merz Aesthetics aesthetic business context | IncobotulinumtoxinA product often discussed through formulation and handling context. |
| Jeuveau | 2019 U.S. label anchor 🔗 | Evolus commercialization; Daewoong Pharmaceutical manufacturing | PrabotulinumtoxinA-xvfs U.S. aesthetic brand connected to Nabota’s Korea-origin product identity. |
| Daxxify | 2022 U.S. label anchor 🔗 | Revance / Crown Laboratories | DaxibotulinumtoxinA-lanm product described by Revance as peptide-formulated. |
| Letybo | 2024 FDA approval snapshot 🔗 | Hugel | LetibotulinumtoxinA-wlbg U.S. aesthetic brand connected to Hugel’s Korea-origin portfolio. |
U.S. Therapeutic Serotype Reference
Section titled “U.S. Therapeutic Serotype Reference”| Brand | U.S. approval anchor | Manufacturer / commercialization context | Product identity |
|---|---|---|---|
| Myobloc / Neurobloc | 2000 U.S. approval letter 🔗 | Supernus Pharmaceuticals current company context | RimabotulinumtoxinB type B reference for therapeutic interpretation, not an aesthetic type A peer. |
International And New Serotype Context
Section titled “International And New Serotype Context”| Brand | Current regulatory anchor | Company context | Product identity |
|---|---|---|---|
| Relfydess | Approved in 33 markets and launched in more than 20 as of July 1, 2026; the U.S. BLA received a CRL. | Galderma | RelabotulinumtoxinA, a Galderma-developed type A product with a ready-to-use liquid presentation. |
| Boey | Canadian approval record in June 2026 and European Commission approval in July 2026; not FDA approved in the United States. | AbbVie / Allergan | TrenibotulinumtoxinE, a type E product distinct from the Botox type A franchise. |
How Brand Names Connect
Section titled “How Brand Names Connect”Product names often travel across companies, licensing arrangements, and regions. Jeuveau connects the U.S. aesthetic label to Daewoong’s Nabota manufacturing identity. Letybo connects the U.S. label to Hugel’s broader Botulax / Letybo product family. Myobloc and Neurobloc show how a type B product may carry different regional names, while Boey shows why a separate type E product should not be folded into the type A comparison set. Relfydess separates Galderma’s own product-development role from its licensed Dysport commercialization role.
Those connections are useful for market mapping, but they do not create one global label. A product name used in one country may have different approval language, vial presentations, indications, or distribution partners elsewhere.
Comparison Paths
Section titled “Comparison Paths”Readers comparing products should start with product identity before asking about clinical use:
| Comparison question | Best starting point |
|---|---|
| Which companies are behind the brand? | The company directory separates developers, manufacturers, owners, and commercialization partners. |
| Is it type A or type B? | Type A vs type B explains serotype differences without implying substitutability. |
| Can units be converted? | Botulinum toxin and product labels explain why unit systems are product-specific. |
| Is a use approved? | Current prescribing information and regulator records define approval in a specific market; the U.S. regulatory reference separates current labels, approval history, and non-approved application stages, while Japan approval context explains how to read Japanese product-information and PMDA-based approval claims. |
Sources
Section titled “Sources”The brand entries rely mainly on prescribing information, regulator records, and official company or commercialization materials. Market visibility, online product pages, and familiar clinical use are not treated as proof of approval or superiority.